Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.…
Accuray Closes TCW Transaction, Strengthening Balance Sheet to Support Long-Term Value Growth
Accuray (NASDAQ: ARAY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 809 employees.
The shares were at 2.075 USD on 20 November 2026, down 95.6% over 52 weeks. Its 52-week range is 2.059 USD to 48.40 USD, and it trades at the bottom of that range.
Its market capitalisation is 6.22M USD.
Accuray reports return on equity of -118.0%, an operating margin of -0.6% and revenue down 7.9% year over year.
Its debt exceeds its cash by 93.72M USD, a debt-to-equity ratio of 4.41. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 3 February 2027.